ABSTRACT
The current repertoire of human assisted reproduction therapies is undergoing constant development and improvement. In-vitro maturation (IVM) of near-grown oocytes and in-vitro growth (IVG) of follicles from early developmental stages are two such technologies, with much clinical potential for several groups of patients.
